Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I randomized double-blind placebo-controlled study of intrathecal Xen2174 in healthy volunteers
NL-OMON32600Phase 1Active, not recruiting
- Sponsor
- Xenome Ltd
- Start
- Oct 2009
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in pain comparing Xen2174 with Placebo (2 arms). Primary endpoint: Overall safety and tolerability. Started Oct 2009; status: active, not recruiting.
02
Drugs
Xen2174
03
Conditions
pain
Beyond the preview
Go deeper on NL-OMON32600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32600.